Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cartibeads
- Development stage
- Unknown
- Lead developer
- Vanarix
- Modality
- Cell Therapies
- Administration
- Implant, Intraarticular
01
Overview
Autologous Cartibeads is an autologous cell therapy consisting of bio-engineered cartilage mini-grafts (microtissues) developed by Vanarix for the treatment of articular cartilage damage, focal knee cartilage lesions, and early osteoarthritis. The therapy is produced by harvesting a patient's own cartilage cells (chondrocytes), expanding and re-differentiating them in vitro, and forming three-dimensional hyaline-like cartilage microtissues (beads). These mini-grafts are then implanted into the damaged joint, where they self-integrate to regenerate high-quality hyaline cartilage, mimicking native articular cartilage and restoring joint function.
- Brand names
- Cartibeads
Beyond the preview
Go deeper on autologous cartibeads.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cartibeads.